INFLAMMATORY BOWEL DISEASE

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease

A Di Sabatino¹, R Ciccocioppo³, B Cinque², D Millimaggi², R Morera¹, L Ricevuti¹, M G Cifone², G R Corazza¹

¹ Gastroenterology Unit, IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy
² Department of Experimental Medicine, University of L’Aquila, L’Aquila, Italy
³ Department of Internal Medicine, University of L’Aquila, L’Aquila, Italy

Correspondence to:
Correspondence to:
Professor G R Corazza
Unità di Gastroenterologia, IRCCS Policlinico San Matteo, Università di Pavia, Piazzale Golgi 5, 27100 Pavia, Italy; gr.corazza{at}smatteo.pv.it

Background and aims: To verify whether targeting defective mucosal T cell death underlies the sustained therapeutic benefit of infliximab in Crohn’s disease, we explored its in vivo proapoptotic effect after 10 weeks of treatment, and its in vitro killing activity on lamina propria T cells (LPT) and peripheral blood T cells (PBT), both isolated from Crohn’s disease patients.

Methods: Endoscopic intestinal biopsies were collected from 10 Crohn’s disease patients (six steroid refractory and four fistulising) before and after three consecutive infusions of infliximab, administered at week 0, 2, and 6 in a single intravenous dose (5 mg/kg), and from 10 subjects who proved to have functional diarrhoea. Apoptosis was determined in vivo by TUNEL assay, and in vitro by fluorescein isothiocyanate-annexin V/propidium iodide staining on LPT and PBT from Crohn’s disease patients cultured with infliximab. The effect of the broad caspase inhibitor Z-VAD-FMK and the neutralising anti-Fas antibody ZB4 was tested in vitro on LPT and PBT treated with infliximab. Caspase-3 activity was determined by immunoblotting.

Results: In Crohn’s disease patients, infliximab treatment induced a sustained LPT apoptosis, still evident four weeks after the last infusion. In vitro infliximab induced death of LPT from Crohn’s disease patients occurred via apoptosis rather than necrosis. LPT showed a higher susceptibility to infliximab induced apoptosis than PBT in Crohn’s disease patients. The signalling pathway underlying the restoration of infliximab induced LPT apoptosis occurred via the caspase pathway but not Fas-Fas ligand interaction in Crohn’s disease.

Conclusions: These findings demonstrate that apoptosis is the major mechanism by which infliximab exerts its killing activity on LPT in Crohn’s disease. The sustained LPT proapoptotic action of infliximab, which extends far beyond its circulating half life, may be responsible for the sustained remission induced in Crohn’s disease patients by infliximab retreatment.

Keywords: apoptosis; Crohn’s disease; infliximab; lamina propria T cells; caspase-3

Abbreviations: CDAI, Crohn’s disease activity index; EDTA, ethylenediamine tetraacetic acid; FasL, Fas ligand; FCS, fetal calf serum; FITC, fluorescein isothiocyanate; IL, interleukin; LPT, lamina propria T cells; PBS, phosphate buffered saline; PBT, peripheral blood T cells; PDAI, perianal disease activity index; PI, propidium iodide; TNF, tumour necrosis factor; TUNEL, terminal deoxynucleotidyl transferase mediated digoxigenin-deoxyuridine triphosphate nick end labelling; Z-VAD-FMK, Z-Val-Ala-Asp(OMe)-monofluoroketone

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Digest

Robin Spiller
Gut 2004 53: 1. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Cantaert, T, De Rycke, L, Mavragani, C P, Wijbrandts, C A, Niewold, T B, Niers, T, Vandooren, B, Veys, E M, Richel, D, Tak, P P, Crow, M K, Baeten, D (2009). Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. Ann Rheum Dis 68: 1022-1029 [Abstract] [Full Text]  
• Ebert, E. C. (2009). Infliximab and the TNF-{alpha} system. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G612-G620 [Abstract] [Full Text]  
• Di Sabatino, A, Pickard, K M, Rampton, D, Kruidenier, L, Rovedatti, L, Leakey, N A B, Corazza, G R, Monteleone, G, MacDonald, T T (2008). Blockade of transforming growth factor {beta} upregulates T-box transcription factor T-bet, and increases T helper cell type 1 cytokine and matrix metalloproteinase-3 production in the human gut mucosa. Gut 57: 605-612 [Abstract] [Full Text]  
• Tsiodras, S., Samonis, G., Boumpas, D. T., Kontoyiannis, D. P. (2008). Fungal Infections Complicating Tumor Necrosis Factor {alpha} Blockade Therapy. Mayo Clin Proc. 83: 181-194 [Abstract] [Full Text]  
• Tran, C. N., Lundy, S. K., White, P. T., Endres, J. L., Motyl, C. D., Gupta, R., Wilke, C. M., Shelden, E. A., Chung, K. C., Urquhart, A. G., Fox, D. A. (2007). Molecular Interactions between T Cells and Fibroblast-Like Synoviocytes: Role of Membrane Tumor Necrosis Factor-{alpha} on Cytokine-Activated T Cells. Am. J. Pathol. 171: 1588-1598 [Abstract] [Full Text]  
• Van den Brande, J. M H, Koehler, T. C, Zelinkova, Z., Bennink, R. J, te Velde, A. A, ten Cate, F. J W, van Deventer, S. J H, Peppelenbosch, M. P, Hommes, D. W (2007). Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 56: 509-517 [Abstract] [Full Text]  
• Mudter, J, Neurath, M F (2007). Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 56: 293-303 [Full Text]  
• Han, X, Benight, N, Osuntokun, B, Loesch, K, Frank, S J, Denson, L A (2007). Tumour necrosis factor {alpha} blockade induces an anti-inflammatory growth hormone signalling pathway in experimental colitis. Gut 56: 73-81 [Abstract] [Full Text]  
• Falconer, H., Mwenda, J.M., Chai, D.C., Wagner, C., Song, X.Y., Mihalyi, A., Simsa, P., Kyama, C., Cornillie, F.J., Bergqvist, A., Fried, G., D'Hooghe, T.M. (2006). Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon. Hum Reprod 21: 1856-1862 [Abstract] [Full Text]  
• Danese, S., Sans, M., Scaldaferri, F., Sgambato, A., Rutella, S., Cittadini, A., Pique, J. M., Panes, J., Katz, J. A., Gasbarrini, A., Fiocchi, C. (2006). TNF-{alpha} Blockade Down-Regulates the CD40/CD40L Pathway in the Mucosal Microcirculation: A Novel Anti-Inflammatory Mechanism of Infliximab in Crohn's Disease. J. Immunol. 176: 2617-2624 [Abstract] [Full Text]  
• Stenger, S (2005). Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann Rheum Dis 64: iv24-iv28 [Abstract] [Full Text]  
• MacDonald, T. T., DiSabatino, A., Gordon, J. N. (2005). Immunopathogenesis of Crohn's Disease. JPEN J Parenter Enteral Nutr 29: S118-S125 [Abstract] [Full Text]  
• Sanders, D S A (2005). Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn's disease. J. Clin. Pathol. 58: 568-572 [Abstract] [Full Text]  
• Gibson, P R (2004). Increased gut permeability in Crohn's disease: is TNF the link?. Gut 53: 1724-1725 [Full Text]  
• Zeissig, S, Bojarski, C, Buergel, N, Mankertz, J, Zeitz, M, Fromm, M, Schulzke, J D (2004). Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor {alpha} antibody treatment. Gut 53: 1295-1302 [Abstract] [Full Text]  

eLetters:

Read all eLetters

Modulation of p38MAPK and STAT3 signalling by infliximab and etanercept in intestinal T-cells

Philip Rosenstiel, et al.

Gut Online, 1 Jul 2004 [Full text]

Re: Modulation of p38MAPK and STAT3 signalling by infliximab and etanercept in intestinal T-cells

Antonio Di Sabatino, et al.

Gut Online, 23 Jul 2004 [Full text]